


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: July 15, 2008 <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,643
				Filing Date	11/18/2003
				First Named Inventor	Peter A. Crooks
				Group Art Unit	1617
				Examiner Name	Gregory W. Mitchell
				Attorney Docket Number	069962-0102
Sheet	1	of	1		



### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Offic e <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	B1	EIDE et al., "Continuous subcutaneous administration of the <i>N</i> -methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia," <i>Pain</i> , 1995 Vol. 61, pages 221-228, Elsevier Science B.V.	
	B2	EIDE et al., "Relief of post-herpetic neuralgia with the <i>N</i> -methyl- aspartic acid (NMDA) receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo," <i>Pain</i> , 1994 Vol. 58, pages 347-354, Elsevier Science B.V.	
	B3	BUSHNELL et al., "Response of chronic neuropathic pain syndromes to ketamine: a role for norketamine?" <i>Pain</i> , 1995, Vol. 60, page 115, Elsevier Science B.V.	
	B4	GRANT et al., "Pharmacokinetics and analgesic effects of I.M. and oral ketamine," <i>Br. J. Anaesth.</i> , 1981 Vol. 53, pages 805-810, Macmillan Publishers LTD.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.